Literature DB >> 21890410

mTOR: A pathogenic signaling pathway in developmental brain malformations.

Peter B Crino1.   

Abstract

The mTOR signaling network functions as a pivotal regulatory cascade during the development of the cerebral cortex. Aberrant hyperactivation of mTOR as a consequence of loss-of-function gene mutations encoding mTOR inhibitor proteins such as TSC1, TSC2, PTEN and STRADα has been recently linked to developmental cortical malformations associated with epilepsy and neurobehavioral disabilities. Investigation of mTOR signaling in these disorders provides for the first time exciting future avenues for assessment of biomarkers, patient stratification and prognostic measures as well as the opportunity for targeted therapy to regulate mTOR activity across all age groups. As we learn more about mTOR and its activity in the developing brain, many challenges will arise that must be overcome before widespread clinical therapeutics can be implemented.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890410     DOI: 10.1016/j.molmed.2011.07.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  86 in total

1.  RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity.

Authors:  Martina Proietti Onori; Linda M C Koene; Carmen B Schäfer; Mark Nellist; Marcel de Brito van Velze; Zhenyu Gao; Ype Elgersma; Geeske M van Woerden
Journal:  PLoS Biol       Date:  2021-05-26       Impact factor: 8.029

2.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.

Authors:  Jeong Ho Lee; My Huynh; Jennifer L Silhavy; Sangwoo Kim; Tracy Dixon-Salazar; Andrew Heiberg; Eric Scott; Vineet Bafna; Kiley J Hill; Adrienne Collazo; Vincent Funari; Carsten Russ; Stacey B Gabriel; Gary W Mathern; Joseph G Gleeson
Journal:  Nat Genet       Date:  2012-06-24       Impact factor: 38.330

3.  Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.

Authors:  Vinit V Patil; Miguel Guzman; Angela N Carter; Geetanjali Rathore; Daniel Yoshor; Daniel Curry; Angus Wilfong; Satish Agadi; John W Swann; Adekunle M Adesina; Meenakshi B Bhattacharjee; Anne E Anderson
Journal:  Neuropathology       Date:  2015-09-18       Impact factor: 1.906

4.  Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR.

Authors:  Richard J Leventer; Thomas Scerri; Ashley P L Marsh; Kate Pope; Greta Gillies; Wirginia Maixner; Duncan MacGregor; A Simon Harvey; Martin B Delatycki; David J Amor; Peter Crino; Melanie Bahlo; Paul J Lockhart
Journal:  Neurology       Date:  2015-04-15       Impact factor: 9.910

Review 5.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

6.  Is focal cortical dysplasia an infectious disease?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2013-09       Impact factor: 7.500

Review 7.  Inflammatory pathways of seizure disorders.

Authors:  Nicola Marchi; Tiziana Granata; Damir Janigro
Journal:  Trends Neurosci       Date:  2013-12-16       Impact factor: 13.837

8.  Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.

Authors:  Adam B Steinmetz; Sarah A Stern; Amy S Kohtz; Giannina Descalzi; Cristina M Alberini
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

Review 9.  Biomarkers in autism spectrum disorder: the old and the new.

Authors:  Barbara Ruggeri; Ugis Sarkans; Gunter Schumann; Antonio M Persico
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

10.  Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.

Authors:  Avery J Zucco; Valentina Dal Pozzo; Alina Afinogenova; Ronald P Hart; Orrin Devinsky; Gabriella D'Arcangelo
Journal:  Mol Cell Neurosci       Date:  2018-08-23       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.